Jennison Associates LLC Prothena Corp Public LTD CO Transaction History

Jennison Associates LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	BUY	$47.3 - $70.6 $300,165 - $448,027	6,346 Added 12.89%	55,579 $2.68 Million
Q1 2023 Apr 26, 2023	SELL	$46.97 - $58.27 $375 - $466	-8 Reduced 0.02%	49,233 $2.39 Million
Q4 2022 Feb 09, 2023	BUY	$52.05 - $65.0 $2.56 Million - $3.2 Million	49,241 New	49,241 $2.97 Million
Q2 2022 Aug 02, 2022	SELL	$22.73 - $39.98 $659 - $1,159	-29 Reduced 0.12%	24,016 $652,000
Q1 2022 May 11, 2022	BUY	$30.27 - $49.22 $163,881 - $266,477	5,414 Added 29.06%	24,045 $879,000
Q4 2021 Feb 08, 2022	BUY	$42.11 - $73.26 $183,599 - $319,413	4,360 Added 30.55%	18,631 $920,000
Q3 2021 Nov 09, 2021	BUY	$48.2 - $78.89 $687,862 - $1.13 Million	14,271 New	14,271 $1.02 Million
Q1 2018 Apr 20, 2018	SELL	$27.95 - $45.04 $11.6 Million - $18.7 Million	-416,031 Closed	0 $0
Q4 2017 Jan 25, 2018	BUY	$35.44 - $63.76 $188,292 - $338,756	5,313 Added 1.29%	416,031 $15.6 Million
Q3 2017 Nov 03, 2017	BUY	$53.83 - $67.75 $22.1 Million - $27.8 Million	410,718	410,718 $26.6 Million

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $645M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.